# US 12,600,764 B2 · Antigen-binding proteins targeting coronavirus (COV) variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,600,764 B2
- Document ID: US12600764B2
- Status: Granted
- Kind: B2
- Application number: 17/459,486
- Filed: 2021-08-27
- Published: 2023-03-09
- Granted: 2026-04-14
- Earliest claimed: 2021-08-27
- Assignees: International Business Machines Corporation
- Applicants: International Business Machines Corporation
- Inventors: Binquan Luan; Leili Zhang; Tien Huynh
- Web page: https://patentgrep.com/patent/US12600764B2

## CPC

- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 14/005: from viruses
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Techniques regarding antigen-binding proteins that can bind to CoV (e.g., SARS-CoV-2) variants are provided. For example, one or more embodiments described herein can comprise an antigen-binding protein that can comprise a heavy polypeptide chain variable region with an amino acid sequence that is a variant of SEQ ID NO: 7. The amino acid sequence can comprise at least one amino acid substitution selected from the group consisting of: R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho, I54D, I54E, I54W, I54F, I54Y, I54Pho, L55D, L55E, L55W, L55F, L55Y, and L55Pho.

## Claims

### Claim 1

An antigen-binding protein, comprising:
a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and
a light polypeptide chain variable region with a second amino acid sequence that is selected from the first group consisting of SEQ ID NO: 18 and SEQ ID NO: 19.

### Claim 2 (depends on 1)

The antigen-binding protein of claim 1, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

### Claim 3 (depends on 2)

The antigen-binding protein of claim 2, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

### Claim 4 (depends on 3)

The antigen-binding protein of claim 3, wherein the binding interaction comprises formation of a salt-bridge.

### Claim 5 (depends on 3)

The antigen-binding protein of claim 3, wherein the binding interaction comprises a cation-n interaction.

### Claim 6

An antigen-binding protein, comprising:
a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and
a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 18.

### Claim 7 (depends on 6)

The antigen-binding protein of claim 6, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

### Claim 8 (depends on 7)

The antigen-binding protein of claim 7, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

### Claim 9 (depends on 8)

The antigen-binding protein of claim 8, wherein the binding interaction comprises formation of a salt-bridge.

### Claim 10

An antigen-binding protein, comprising:
a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and
a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 19.

### Claim 11 (depends on 10)

The antigen-binding protein of claim 10, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

### Claim 12 (depends on 11)

The antigen-binding protein of claim 11, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

### Claim 13 (depends on 11)

The antigen-binding protein of claim 11, wherein the binding interaction comprises formation of a salt-bridge.

### Claim 14 (depends on 11)

The antigen-binding protein of claim 11, wherein the binding interaction comprises a cation-π interaction.